Migra Therapeutics
Industry: Nanotechnology therapy for cancer
Led by researchers at Emory University, Migra Therapeutics is developing next-generation nanotechnology therapies for cancer.
Some types of cancer, particularly pancreatic cancer and breast cancer, are comprised of dense barrier cells called “stroma,” which resist penetration by drug therapy. Migra Therapeutics has engineered a protein that targets a receptor in these cancer cells; the protein binds to the cancer cells to deliver therapies more effectively. Migra’s system can be used to deliver chemotherapy drugs, therapeutic antibodies and most importantly, nanoparticle drugs.
Early testing of the company’s targeted drug delivery system has shown promising results for treating pancreatic and breast cancer. More testing is needed, but the company aims to fundamentally change the future of nanotechnology cancer treatment.
